Entinostat is predicted to have the potential to alleviate the symptoms of HD by inhibiting the functions of histone deacetylase genes such as HDAC1 and HDAC6 (see Fig. 6B), and one of the predicted 3-hop BKG-based MOA paths (“Entinostat” → “decreases activity of” → “HDAC1 gene” → “interacts with” → “Histone H4” → “gene associated with condition” → “Huntington’s disease”) is supported by the previous research [79, 80]. The gene discussed is HDAC1; the disease is juvenile Huntington disease.